Skip to main content
SpringerLink
Log in

Accidental Iatrogenic Intoxications by Cytotoxic Drugs

Error Analysis and Practical Preventive Strategies

  • Original Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Objectives

Drug errors are quite common. Many of them become harmful only if they remain undetected, ultimately resulting in injury to the patient. Errors with cytotoxic drugs are especially dangerous because of the highly toxic potential of the drugs involved. For medico-legal reasons, only 1 case of accidental iatrogenic intoxication by cytotoxic drugs tends to be investigated at a time, because the focus is placed on individual responsibility rather than on system errors. The aim of our study was to investigate whether accidental iatrogenic intoxications by cytotoxic drugs are faults of either the individual or the system. The statistical analysis of distribution and quality of such errors, and the in-depth analysis of contributing factors delivered a rational basis for the development of practical preventive strategies.

Methods

A total of 134 cases of accidental iatrogenic intoxication by a cytotoxic drug (from literature reports since 1966 identified by an electronic literature survey, as well as our own unpublished cases) underwent a systematic error analysis based on a 2-dimensional model of error generation. Incidents were classified by error characteristics and point in time of occurrence, and their distribution was statistically evaluated. The theories of error research, informatics, sensory physiology, cognitive psychology, occupational medicine and management have helped to classify and depict potential sources of error as well as reveal clues for error prevention.

Results

Monocausal errors were the exception. In the majority of cases, a confluence of unfavourable circumstances either brought about the error, or prevented its timely interception. Most cases with a fatal outcome involved erroneous drug administration. Object-inherent factors were the predominant causes. A lack of expert as well as general knowledge was a contributing element. In error detection and prevention of error sequelae, supervision and back-checking are essential. Improvement of both the individual training and work environment, enhanced object identification by manufacturers and hospitals, increased redundancy, proper usage of technical aids, and restructuring of systems are the hallmarks for error prevention.

Conclusions

Errors follow general patterns even in oncology. Complex interdependencies of contributing factors are the rule. Thus, system changes of the working environment are most promising with regard to error prevention. Effective error control involves adapting a set of basic principles to the specific work environment. The work environment should allow for rectification of errors without penalty. Regular and ongoing intra-organisational error analysis needs to be an integral part of any error prevention strategy. However, it seems impossible to totally eliminate errors. Instead, if the environment guarantees timely error interception, most sequelae are avoided, and errors transform into a system-wide learning tool.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Society of Hospital Pharmacists, American Medical Association, American Nurses Association, American Society of Hospital Pharmacists. Understanding and preventing drug misadventures. Proceedings of a multidisciplinary invitational conference; 1994 Oct 21–23. Am J Health Syst Pharm 1995; 52: 369–416

    Google Scholar 

  2. Addiego JE Jr, Ridgway D, Bleyer WA. The acute management of intrathecal methotrexate overdose: pharmacologic rationale and guidelines. J Pediatr 1981; 98: 825–8

    Article  PubMed  Google Scholar 

  3. Al Fawaz IM. Fatal myeloencephalopathy due to intrathecal vincristine administration. Ann Trop Paediatr 1992; 12: 339–42

    PubMed  CAS  Google Scholar 

  4. Anonymous. Inquests — MEq-Mg mix-up ‘lead to death’. Pharm J 1977; 219: 139

  5. Aricó M, Nespoli L, Porta F, et al. Severe acute encephalopathy following inadvertent intrathecal doxorubicin administration. Med Pediatr Oncol 1990; 18: 261–3

    Article  PubMed  Google Scholar 

  6. Attilio RM. Caring enough to understand: road to oncology medication error prevention. Hosp Pharm 1996; 31: 17–26

    Google Scholar 

  7. Baer MR, King LE, Wolff SN. Palmar-plantar erythrodysesthesia and cytarabine. Ann Intern Med 1985; 102: 556

    PubMed  CAS  Google Scholar 

  8. Bain PG, Lantos PL, Djurovic V, et al. Intrathecal vincristine: a fatal chemotherapeutic error with devastating central nervous system effects. J Neurol 1991; 238: 230–4

    Article  PubMed  CAS  Google Scholar 

  9. Barna P. Vincristin overdose [letter]. Clin Pediatr (Phila) 1980; 19: 440

    CAS  Google Scholar 

  10. Beer M, Cavalli F, Martz G. Vincristine overdose: treatment with and without leucovorin rescue [letter]. Cancer Treat Rep 1983; 67: 746–7

    PubMed  CAS  Google Scholar 

  11. Berenson MP. Recovery after inadvertent massive overdose of vincristin (NSC-67574). Cancer Treat Rep 1971; 55: 525–6

    CAS  Google Scholar 

  12. Bleck TP, Jacobsen J. Prolonged survival following the inadvertent intrathecal administration of vincristine: clinical and electrophysiologic analyses. Clin Neuropharmacol 1991; 14: 457–62

    Article  PubMed  CAS  Google Scholar 

  13. Brahams D. Medicine and the law. Manslaughter and reckless medical treatment. Lancet 1991; 338: 1198–9

    Article  PubMed  CAS  Google Scholar 

  14. Brivet F, Pavlovitch JM, Gouyette A, et al. Inefficiency of early prophylactic hemodialysis in cis- platinum overdose. Cancer Chemother Pharmacol 1986; 18: 183–4

    Article  PubMed  CAS  Google Scholar 

  15. Cancer center airs investigators’ findings on overdose incidents, cites subsequent system changes. Am J Health Syst Pharm 1995; 52: 2631-2

    Google Scholar 

  16. Casteels-Van-Daele M, Beirinckx J, Baines P. Overdose with vincristine. J Pediatr 1977; 90: 1042–3

    Google Scholar 

  17. Chagnon A, Jean P, Hautville D, et al. Accidents toxiques aigus dus à l’administration accidentelle d’une dose excessive de vincaleucoblastine. MM No. 107 Sept/2

  18. Choonara IA, Kendall-Smith S, Bailey CC. Accidental actinomycin D overdose in man, a case report. Cancer Chemother Pharmacol 1988; 21: 173–4

    Article  PubMed  CAS  Google Scholar 

  19. Chu G, Mantin R, Shen YM, et al. Massive cisplatin overdose by accidental substitution for carboplatin: toxicity and management. Cancer 1993; 72: 3707–14

    Article  PubMed  CAS  Google Scholar 

  20. Coates TD. Survival from melphalan overdose. Lancet 1984; II: 1048

    Article  Google Scholar 

  21. Cohen MR. Medication error reports. Hosp Pharm 1977; 12: 100–1

    Google Scholar 

  22. Cohen MR. Medication error reports. Hosp Pharm 1990; 25: 266–7

    Google Scholar 

  23. Cohen MR. Safety alert — overdose of platinol (cisplatin) and paraplatin (carboplatin) and a dangerous abbreviation. Hosp Pharm 1992; 27: 991–2

    Google Scholar 

  24. Cohen MR. Adria, a dangerous abbreviation for adriamycin, looks like aredia. Hosp Pharm 1994; 29: 141–58

    Google Scholar 

  25. Cohen MR. Another vincristine tragedy: what are you doing to make sure this doesn’t happen to you? Hosp Pharm 1994; 29: 725–6

    Google Scholar 

  26. Cohen MR. Accidental overdose of investigational drug because of a misunderstood label. Hosp Pharm 1995; 30: 70–3

    Google Scholar 

  27. Cohen MR. Preventing daunorubicin (cerubidine) —doxorubicin mix-ups. Hosp Pharm 1996; 31: 184–7

    Google Scholar 

  28. Cohen MR. Liposomal doxorubicin formulation confused with conventional doxorubicin. Hosp Pharm 1997; 32: 44–51

    Google Scholar 

  29. Conter V, Rabbone ML, Jankovic M, et al. Overdose of vinblastine in a child with Langerhans’ cell histiocytosis: toxicity and salvage therapy. Pediatr Hematol Oncol 1991; 8: 165–9

    Article  PubMed  CAS  Google Scholar 

  30. Curran CF. Acute doxorubicin overdoses [letter]. Ann Intern Med 1991; 115: 913–4

    PubMed  CAS  Google Scholar 

  31. Czaykowski PM, Samuels T, Oza A. A durable response to cytarabine in advanced breast cancer. Clin Oncol 1997; 9: 181–3

    Article  CAS  Google Scholar 

  32. Dyke RW. Treatment of inadvertent intrathecal injection of vincristine [letter]. N Engl J Med 1989; 321: 1270–1

    PubMed  CAS  Google Scholar 

  33. Ettinger LJ, Freeman AI, Creaven PJ. Intrathecal methotrexate overdose without neurotoxicity: case report and literature review. Cancer 1978; 41: 1270–3

    Article  PubMed  CAS  Google Scholar 

  34. Ettinger LJ. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose. Cancer 1982; 50: 444–50

    Article  PubMed  CAS  Google Scholar 

  35. Fassoulaki A, Pavlou H. Overdosage intoxication with cisplatin-a cause of acute respiratory failure. J R Soc Med 1989; 82: 689

    PubMed  CAS  Google Scholar 

  36. Fernandez MN, Cabrera R, Sanjuan I, et al. Hypertension, grand mal epilepsy, intestinal dyskinesia, sensitive motor neuropathy and hyponatremia resulting from acute vincristine overdose. Sangre 1981; 26: 209–15

    PubMed  CAS  Google Scholar 

  37. Fiorentino MV, Salvagno L, Chiarion Sileni V, et al. Vindesine overdose [letter]. Cancer Treat Rep 1982; 66: 1247–8

    PubMed  CAS  Google Scholar 

  38. Fritsch J. Syracuse hospital admits causing death of patient. New York Times 1992, May 13: B5

  39. Gaidys WG, Dickermann JD, Walters CL, et al. Intrathecal vincristine. Report of a fatal case despite CNS washout. Cancer 1983; 52: 799–801

    Article  PubMed  CAS  Google Scholar 

  40. Gebbia V, Palmeri S, Russo A, et al. Toxicity secondary to cisdiamminedichloro-platinum overdose: a case report. Int J Exp Clin Chemother 1989; 2: 219–24

    Google Scholar 

  41. Grush OC, Morgan SK. Folinic acid rescue for vincristine toxicity. Clin Toxicol 1979; 14: 71–8

    Article  PubMed  CAS  Google Scholar 

  42. Hachimi-Idrissi S, Schots R, DeWolf D, et al. Reversible cardiopathy after accidental overdose of mitoxantrone. Pediatr Hematol Oncol 1993; 10: 35–40

    Article  PubMed  CAS  Google Scholar 

  43. Hanson DS, Leggette CT. Severe hypotension following inadvertent intravenous administration of interferon alpha 2a. Ann Pharmacother 1997; 31: 371–2

    PubMed  CAS  Google Scholar 

  44. Haupt R, Perin G, Dallorso S, et al. Very high dose cisplatin (450 mg/m2) in an infant with rhabdomyosarcoma. Anticancer Res 1989; 9: 427–8

    PubMed  CAS  Google Scholar 

  45. Jakobson ÅM, Kreuger A, Mortimer O, et al. Cerebrospinal fluid exchange after intrathecal methotrexate overdose: a report of two cases. Acta Paediatr 1992; 81: 359–61

    Article  PubMed  CAS  Google Scholar 

  46. Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol 1996; 18: 302–4

    Article  PubMed  CAS  Google Scholar 

  47. Jochimsen PR. Subacute vincristine toxicity following five consecutive doses. Am J Clin Oncol 1982; 5: 437–41

    Article  PubMed  CAS  Google Scholar 

  48. Jost LM. Überdosierung von Melphalan (AlkeranR): Symptome und Behandlung. Eine Übersicht. Onkologie 1990; 13: 96–101

    Article  PubMed  CAS  Google Scholar 

  49. Jungi WF. Häufige Fehler bei der Planung und Durchführung von Tumortherapien. Schweiz Rundsch Med Prax 1991; 80: 196–9

    PubMed  CAS  Google Scholar 

  50. Kaufman IA, Kung FH, Koenig HM, et al. Overdose with vincristine. J Pediatr 1976; 89: 671–4

    Article  PubMed  CAS  Google Scholar 

  51. Kim IS, Gratwohl A, Stebler C, et al. Accidental overdose of multiple chemotherapeutic agents. Korean J Intern Med 1989; 4: 171–3

    PubMed  Google Scholar 

  52. Kosmidis HV, Bouhoutsou DO, Varvoutsi MC, et al. Vincristine overdose: experience with 3 patients. Pediatr Hematol Oncol 1991; 8: 171–8

    Article  PubMed  CAS  Google Scholar 

  53. Lafolie P, Liliemark J, Björk O, et al. Exchange of cerebrospinal fluid in accidental intrathecal overdose of cytarabine. Med Toxicol Drug Exp 1988; 3: 248–52

    CAS  Google Scholar 

  54. Lampkin BC, Higgins GR, Hammond D. Absence of neurotoxicity following massive intrathecal administration of methotrexate. Cancer 1967; 20: 1780–1

    Article  PubMed  CAS  Google Scholar 

  55. Langslow A. Nursing and the law. Carelessness in cancer care. Aust Nurs J 1996; 4: 32–4

    Google Scholar 

  56. Laskoski G. Fatal mixup. Am Drug 1992; 205: 15

    Google Scholar 

  57. Lau G. Accidental intraventricular vincristine administration: an avoidable iatrogenic death. Med Sci Law 1996; 36: 263–5

    PubMed  CAS  Google Scholar 

  58. Leblanc T, Chevallier B, Doz F, et al. Injection intrathécale accidentelle d’une forte dose de méthotrexate: proposition d’un schéma thérapeutique à propos d’une observation. Ann Pediatr Paris 1987; 34: 453–4

    PubMed  CAS  Google Scholar 

  59. Lee ACW, Wong KW, Fong KW, et al. Intrathecal methotrexate overdose. Acta Paediatr Int J Paediatr 1997; 86: 434–7

    Article  CAS  Google Scholar 

  60. Lindahl CE. Överdosering — dödsfall. Vardfacket 1979; 3: 73

    PubMed  CAS  Google Scholar 

  61. Lotz JP, Chapiro J, Voinea A, et al. Overdosage of vinorelbine in an women with metastatic non-small cell lung carcinoma. Ann Oncol 1997; 8: 714–5

    Article  PubMed  CAS  Google Scholar 

  62. Maeda K, Ueda M, Ohtaka H, et al. A massive dose of vincristine. Jpn J Clin Oncol 1987; 17: 247–53

    PubMed  CAS  Google Scholar 

  63. Manelis J, Freudlich E, Ezekiel E, et al. Accidental intrathecal vincristine administration: report of a case. J Neurol 1982; 228: 209–13

    Article  PubMed  CAS  Google Scholar 

  64. Michelagnoli MP, Bailey CC, Wilson I, et al. Potential salvage therapy for inadvertent intrathecal administration of vincristine. Br JHaematol 1997; 99: 364–7

    Article  CAS  Google Scholar 

  65. Montauk L. Doctors and manslaughter [letter]. Lancet 1991; 338: 1599

    Article  PubMed  CAS  Google Scholar 

  66. Morrissey J. State probe shows Dana-Farber failed to follow basic protocols. Mod Healthc 1995; 25: 82–4

    PubMed  CAS  Google Scholar 

  67. Mortensen ME, Cecalupo AJ, Lo WD, et al. Inadvertent intrathecal injection of daunorubicin with fatal outcome. Med Pediatr Oncol 1992; 20: 249–53

    Article  PubMed  CAS  Google Scholar 

  68. O’Marcaigh AS, Johnson CM, Smithson WA, et al. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc 1996; 71: 161–5

    Article  PubMed  Google Scholar 

  69. Pierga JY, Beuzeboc P, Dorval T, et al. Favourable outcome after plasmapheresis for vincristine overdose [letter]. Lancet 1992; 340: 185

    Article  PubMed  CAS  Google Scholar 

  70. Pike IM, Arbus MH. Cisplatin overdose. Oncol Nurs Forum 1992; 19: 1163

    PubMed  CAS  Google Scholar 

  71. Robbins G. Accidental intrathecal injection of vindesine. BMJ 1985; 291: 1094

    Article  Google Scholar 

  72. Schiller JH, Rozental J, Tutsch KD, et al. Inadvertent administration of 480 mg/m2 of cisplatin. Am J Med 1989; 86: 624–5

    Article  PubMed  CAS  Google Scholar 

  73. Schochet SS, Lampert PW, Earle KM. Neuronal change induced by intrathecal vincristine sulfate. J Neuropathol Exp Neurol 1968; 27: 645–58

    Article  PubMed  Google Scholar 

  74. Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: possible reversal by n-acetylcysteine treatment. J Am Soc Nephral 1997; 8: 1640–4

    CAS  Google Scholar 

  75. Shepherd DA, Steuber CP, Starling KA, et al. Accidental intrathecal administration of vincristine. Med Pediatr Oncol 1978; 5: 85–8

    Article  PubMed  CAS  Google Scholar 

  76. Siegert W, Hiddemann W, Koppensteiner R, et al. Accidental overdose of mitoxantrone in three patients. Med Oncol Tumor Pharmacother 1989; 6: 275–8

    PubMed  CAS  Google Scholar 

  77. Slimowitz R. Thoughts on a medical disaster. Am J Health Syst Pharm 1995; 52: 1464–5

    PubMed  CAS  Google Scholar 

  78. Slyter H, Liwnicz B, Herrick MK, et al. Fatal myeloencephalopathy caused by intrathecal vincristine. Neurology 1980; 30: 867–71

    Article  PubMed  CAS  Google Scholar 

  79. Spiegel RJ, Cooper PR, Blum RH, et al. Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 1984; 311: 386–8

    Article  PubMed  CAS  Google Scholar 

  80. Stahel RA, Oelz O. Syndrome of inappropriate ADH secretion secondary to vinblastin. Cancer Chemother Pharmacol 1982; 8: 253–4

    Article  PubMed  CAS  Google Scholar 

  81. Steger GG, Mader RM, Gnant MFX, et al. GM-CSF in the treatment of a patient with severe methotrexate intoxication. J Intern Med 1993; 233: 499–502

    Article  PubMed  CAS  Google Scholar 

  82. Stones DK. Vincristine overdosage in paediatric patients. Med Pediatr Oncol 1998; 30: 193

    Article  PubMed  CAS  Google Scholar 

  83. Suskind RM, Brusilow SW, Zehr J. Syndrome of inappropriate secretion of antidiuretic hormone produced by vincristine toxicity (with bioassay of ADH level). J Paediatr 1972; 81: 90–8

    Article  CAS  Google Scholar 

  84. Takada SI, Chen SZ, Mori H. Toxicity of vincristine overdose in a patient with invasive mole. J Jpn Soc Cancer Ther 1989; 24: 2617–23

    CAS  Google Scholar 

  85. Thomas LL, Braat PC, Somers R, et al. Massive vincristine overdose: Failure of leucovorin to reduce toxicity. Cancer Treat Rep 1982; 66: 1967–9

    PubMed  CAS  Google Scholar 

  86. Vik T, Slørdahl S, Moe PJ. An overdose of vincristine in an eleven-year old boy. Eur Paediatr Haematol Oncol 1985; 2: 167–70

    Article  Google Scholar 

  87. Wakem CJ, Bennett JM. Inappropriate ADH secretion associated with massive vincristine overdosage. Aust N Z J Med 1975; 5: 266–9

    Article  PubMed  CAS  Google Scholar 

  88. Wegelius R. An overdose of vincristine [letter]. Pediatr Hematol Oncol 1987; 4: 173–5

    Article  PubMed  CAS  Google Scholar 

  89. Weissman SJ, Berkow RL, Weetman RM, et al. 5-Azacytidine: acute central nervous system toxicity. Am J Pediatr Hematol Oncol 1985; 7: 86–8

    Google Scholar 

  90. Williams ME, Walker AN, Bracikowski JP, et al. Ascending myeloencephalopathy due to intrathecal vincristine sulfate: a fatal chemotherapeutic error. Cancer 1983; 51: 2041–7

    Article  PubMed  CAS  Google Scholar 

  91. Winter SC, Arbus GS. Syndrome of inappropriate secretion of antidiuretic hormone secondary to vinblastine overdose [letter]. Can Med Assoc J 1977; 117: 1134

    PubMed  CAS  Google Scholar 

  92. Yoffe G, Rice L, Alfrey CP Jr., et al. Case report. Depressive reaction to vincristin overdose [letter]. Clin Lab Haematol 1986; 8: 80–1

    PubMed  CAS  Google Scholar 

  93. Zaniboni A, Simonicini E, Marpicati P, et al. Severe delayed neurotoxicity after accidental high- dose nitrogen mustard [letter]. Am J Hematol 1988; 27: 305

    Article  PubMed  CAS  Google Scholar 

  94. Zaragoza MR, Ritchey ML, Walter A. Neurologic consequences of accidental intrathecal vincristine: a case report. Med Pediatr Oncol 1995; 24: 61–2

    Article  PubMed  CAS  Google Scholar 

  95. Raju TNK, Kecskes S, Thornton JP, et al. Medication errors in neonatal and paediatric intensive-care units. Lancet 1989; II: 374–6

    Article  Google Scholar 

  96. Anonymous. Wisconsin reviews state code on medication error reporting (news). Am J Hosp Pharm 1994; 51: 1145-6

  97. Allan EL, Barker KN. Fundamentals of medication error research. Am J Hosp Pharm 1990; 47: 555–71

    PubMed  CAS  Google Scholar 

  98. Ness JE, Sullivan SD, Stergachis A. Accuracy of technicians and pharmacists in identifying dispensing errors. Am J Hosp Pharm 1994; 51: 354–7

    PubMed  CAS  Google Scholar 

  99. Davis NM, Cohen MR. Purpose of medication will reduce errors. Am Pharm 1992; NS32: 22–3

    Google Scholar 

  100. Favier M, de Cazanove F, Saint-Martin F, et al. Preventing medication errors in antineoplastic therapy. Am J Hosp Pharm 1994; 51: 832–3

    PubMed  CAS  Google Scholar 

  101. Lesar TS, Briceland LL, Delcoure K, et al. Medication prescribing errors in a teaching hospital. JAMA 1990; 263: 2329–34

    Article  PubMed  CAS  Google Scholar 

  102. Anonymous. Cancer doctor resigns. USA TODAY. International ed. Friday, May 12, 3A, 1995

  103. Peterson AM, Schwarz LR, Veatch RM. Asking a pharmacist to resign for making an error. Am J Health Syst Pharm 1996; 53: 760–3

    PubMed  CAS  Google Scholar 

  104. Manasse HR. Medication use in an imperfect world: drug misadventuring as an issue of public policy. Pt 1. Am J Hosp Pharm 1989; 46: 929–44

    PubMed  Google Scholar 

  105. McCarthy ID, Cohen MR, Kateiva J, et al. What should a pharmacy manager do when a serious medication error occurs?: a panel discussion. Am J Hosp Pharm 1992; 49: 1405–12

    PubMed  CAS  Google Scholar 

  106. Fitts PM, Jones RE. Analysis of factors contributing to 460 pilot-error experiences in operating aircraft controls. In: Sinaiko WH, editors. Selected papers on human factors in the design and use of control systems. New York, Dover, 1961

  107. Heckhausen H. Intentionsgeleitetes Handeln und seine Fehler. In: Heckhausen H, Gollwitzer PM, Weinert FE, editors. Jenseits des Rubikon: Der Wille in den Humanwissenschaften. Berlin: Springer, 1987: 143–175

    Chapter  Google Scholar 

  108. Heckhausen H, Beckmann J. Intentional action and action slips. Psychol Rev 1990; 1: 36–48

    Article  Google Scholar 

  109. Meister D. Human factors in reliability. In: Ireson WG, editor. Reliability handbook. New York: McGraw-Hill, 1966

    Google Scholar 

  110. Reason J, Mycielska K. Absent-minded?: the psychology of mental lapses and everyday errors. Englewood Cliffs: Prentice-Hall, 1982

    Google Scholar 

  111. Singleton WT. Theoretical approaches to human error. Ergonomics 1973; 16: 637–727

    Google Scholar 

  112. Swain AD, Guttmann HE. Handbook of human reliability analysis with emphasis on nuclear power plant applications. Sandia National Laboratories, NUREG/CR-1278, Washington DC: US Nuclear Regulatory Commission, 1984

    Google Scholar 

  113. Wehner T. Sicherheit als Fehlerfreundlichkeit: arbeits- und sozialpsychologische Befunde für eine kritische Technikbewertung. Opladen: Westdeutscher Verlag, 1992

    Google Scholar 

  114. Wehner T, Stade M. The cognitive organisation of human errors: a gestalt theory perspective. Appl Psych Int Rev 1994; 43: 565–84

    Article  Google Scholar 

  115. Wehner T. Fehler und Fehlhandlungen. In: Luczak H, Volpert W, editors. Handbuch Arbeitswissenschaft. Berlin: Springer, 1993

    Google Scholar 

  116. Zimolong B. Fehler und Zuverläßigkeit. In: Hoyos CG, Zimolong B, editors. Ingenieurspsychologie. Göttingen: Hogrefe, 1992

    Google Scholar 

  117. Herczeg M. Software Ergonomie. Grundlagen der Mensch-Computer Kommunikation. Bonn: Addison-Wesley, 1994

    Google Scholar 

  118. Schmidt RF, Thews G. Physiologie des Menschen. Berlin: Springer, 1995

    Google Scholar 

  119. Anderson JR. Cognitive psychology and its implications. New York: Freeman, 1985

    Google Scholar 

  120. Koblitz K. Redundanz und Information. Informatik 1969; 16: 5–10

    Google Scholar 

  121. Shannon CE, Weaver W The mathematical theory of communication. Urbana: University of Illinois Press, 1980

    Google Scholar 

  122. Wersig G. Information — Kommunikation — Dokumentation. München-Pullach: Verlag Dokumentation, 1971

    Google Scholar 

  123. Flynn RR. An introduction to information science. New York: Marcel Dekker, 1987

    Google Scholar 

  124. Zernikow B, Michel E, Jacobs C, et al. Kreatives Zeitmanagement im Krankenhaus. Monatsschr Kinderheilkd 1996; 144: 627–35

    Google Scholar 

  125. Betz RP, Levy HB. An interdisciplinary method of classifying and monitoring medication errors. Am J Hosp Pharm 1985; 42: 1724–32

    PubMed  CAS  Google Scholar 

  126. Cherubim D. Fehlerlinguistik: Beiträge zum Problem der sprachlichen Abweichung. Tübingen: Niemeyer, 1980

    Google Scholar 

  127. Cochran WG. The ϰ2 test of goodness of fit. Ann Math Statist 1952; 23: 315–45

    Article  Google Scholar 

  128. Cochran WG. Some methods for strengthening the common ϰ2 tests. Biometrics 1954; 10: 417–51

    Article  Google Scholar 

  129. Siegel S. Non-parametric statistics for the behavioral science. New York: McGraw Hill, 1956

    Google Scholar 

  130. Hartwig SC, Denger SD, Schneider PJ. Severity-indexed, incident report-based medication error-reporting program. Am J Hosp Pharm 1991; 48: 2611–6

    PubMed  CAS  Google Scholar 

  131. Byrd L. A quality assurance study of medication errors in a psychiatric hospital. Top Health Record Manage 1984; 2: 61–7

    Google Scholar 

  132. Fischer DS, Alfano S, Knobf MT, et al. Improving the cancer chemotherapy use process. J Clin Oncol 1996; 14: 3148–55

    PubMed  CAS  Google Scholar 

  133. Folli HL, Poole RL, Benitz WE, et al. Medication error prevention by clinical pharmacists in two children’s hospitals. Pediatrics 1987; 79: 718–22

    PubMed  CAS  Google Scholar 

  134. Rupp MT. Screening for prescribing errors. Am Pharm 1991; NS31: 71–8

    PubMed  CAS  Google Scholar 

  135. Currie M, Mackay P, Morgan C, et al. The ‘wrong drug’ problem in anaesthesia: an analysis of 2000 incident reports. Anaesth Intensive Care 1993; 21: 596–601

    PubMed  CAS  Google Scholar 

  136. Gold DR, Rogacz S, Bock N, et al. Rotating shift work, sleep, and accidents related to sleepiness in hospital nurses. Am J Public Health 1992; 82: 1011–4

    Article  PubMed  CAS  Google Scholar 

  137. ASHP guidelines on preventing medication errors in hospitals. Am J Hosp Pharm 1993; 50: 305-14

    Google Scholar 

  138. Donchin Y, Gopher D, Olin M, et al. A look into the nature and causes of human errors in the intensive care unit. Crit Care Med 1995; 23: 294–300

    Article  PubMed  CAS  Google Scholar 

  139. Fuqua RA, Stevens KR. What we know about medication errors: a literature review. J Nurs Qual Assur 1988; 3: 1–17

    PubMed  CAS  Google Scholar 

  140. Davis NM. 1700 medical abbreviations: convenience at the expense of communication and safety. Hosp Pharm 1983; 18: 180–97

    Google Scholar 

  141. Davis NM. Teaching patients to prevent errors. Am J Nurs 1994; 94: 17

    Google Scholar 

  142. Davis NM, Cohen MR. Learning lessons from dispensing errors. Am Pharm 1994; NS34: 27–8

    PubMed  CAS  Google Scholar 

  143. Buchanan TL. On the effect of varying levels of illumination on the prescription dispensing error rate in an army high-volume outpatient pharmacy service. Auburn: Auburn University Press, 1989

    Google Scholar 

  144. Allan EL. Relationship among facility design variables and medication errors in an pharmacy [dissertation]. Auburn: Auburn University, 1994

    Google Scholar 

  145. Flynn EA, Barker KN, Gibson JT, et al. Relationship between ambient sounds and accuracy of pharmacists’ prescriptionfilling performance. Hum Factors 1996; 38: 614–22

    Article  PubMed  CAS  Google Scholar 

  146. Embrey DE, Humphreys P, Rosa EA, et al. SLIM-MAUD: An approach to assessing human error probabilities using structured expert judgement. Washington DC: US nuclear Regulatory Commission, 1984

    Google Scholar 

  147. Graumann CF. Handbuch der Psychologie. Vol. 7. Sozialpsychologie. Göttingen: Holzgreve, 1972

    Google Scholar 

  148. AHFS drug information 92. McEvoy GK, editor. Vincristine sulfate. Bethesda: American Society of Hospital Pharmacists, 1992

  149. Davis NM. Cisplatin-carboplatin mix ups: current and future concerns. Hosp Pharm 1994; 29: 1077, 1097

    Google Scholar 

  150. Haran C, Rengel AM. Color coding can prevent mishaps. J Ophthal Nurs Technol 1985; 4: 28–9

    CAS  Google Scholar 

  151. Kusch M, Labouvie H, Bode U. Einflüsse auf die Bewältigung der ersten Behandlungsphase in der pädiatrischen Onkologie. Sozialpädiatrie 1994; 16: 629–35

    Google Scholar 

  152. Kusch M, Vetter C, Bode U. Stationäre, psychologische Betreuung: Ein Konzept der behandlungsbegleitenden psychosozialen Versorgung. Praxis Kinderpsychol Kinderpsychiatrie 1993; 42: 316–26

    CAS  Google Scholar 

  153. Biabace R. Individualistic and organizational analyses of informed consent. Fam Syst Med 1991; 9: 297–306

    Article  Google Scholar 

  154. Ruccione K, Kramer RF, Moore IK, et al. Informed consent for treatment of childhood cancer: factors affecting parents’ decision making. J Pediatr Oncol Nurs 1991; 8: 112–21

    Article  PubMed  CAS  Google Scholar 

  155. Bachert A, Schilling F. Computer assisted therapy planning in pediatric oncology. Ann Hematol 1993; 67 Suppl.: A4

    Google Scholar 

  156. Berard CM, Mahoney CD, Welch DW, et al. Computer software for pharmacy oncology services. Am J Health Syst Pharm 1996; 53: 752–6

    PubMed  CAS  Google Scholar 

  157. Stoner NS, Tanfield CJ, Talbot DC. Computerised prescibing of chemotherapy reduces errors. BMJ 1996; 312: 707

    Article  PubMed  CAS  Google Scholar 

  158. Boyce B, Herrier R. Obtaining and using patient information. Am Pharm 1991; NS31: 517–23

    Google Scholar 

  159. Thorn DB, Sexton MG, LeMay AP, et al. Effects of a cancer chemotherapy prescription form on prescription completeness. Am J Hosp Pharm 1989; 46: 1802–6

    PubMed  CAS  Google Scholar 

  160. Olsen M. Order sheets help prevent chemotherapy administration errors. Oncol Nurs Forum 1997; 24: 802–3

    PubMed  CAS  Google Scholar 

  161. Herschbach P. Psychische Belastung von Ärzten und Krankenpflegekräften. Weinheim: VCH Edition Medizin, 1991

    Google Scholar 

  162. Norman DA. New views of information processing: implication for intelligent decision support systems. In: Hollnagel E, Mancini G, Woods DD, editors. Intelligent decision support in process environment. Berlin: Springer, 1986

    Google Scholar 

  163. Draft guidelines on preventable medication errors. Am J Hosp Pharm 1992; 49: 640-8

    Google Scholar 

  164. Moe PJ, Hertz H, Ludvigsson J, et al. Feilmedisinering af cytostatika hosbarn-profylaske og terapi. Nord Med 1986; 101: 223–5

    Google Scholar 

  165. Trinkle R, Wu JK. Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol 1997; 26: 344–51

    Article  Google Scholar 

  166. Adamson PC, Balis FM, McCully CL, et al. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol 1991; 9: 670–4

    PubMed  CAS  Google Scholar 

  167. Dorr R. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991; 18 Suppl. 2: 48–58

    PubMed  CAS  Google Scholar 

  168. Thomas LL, Mertens MJ, von dem Borne AE, et al. Clinical management of cytotoxic drug overdose. Med Toxicol Adv Drug Exp 1988; 3: 253–63

    CAS  Google Scholar 

  169. Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol 1996; 19: 302–4

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatric Haematology/Oncology, University Children’s Hospital, Bonn, Germany

    Boris Zernikow, Gudrun Fleischhack & Udo Bode

  2. Emma Children’s Hospital, PICU, Academic Medical Centre AMC, University of Amsterdam, Amsterdam, The Netherlands

    Erik Michel

Authors
  1. Boris Zernikow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gudrun Fleischhack
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Udo Bode
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Boris Zernikow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zernikow, B., Michel, E., Fleischhack, G. et al. Accidental Iatrogenic Intoxications by Cytotoxic Drugs. Drug-Safety 21, 57–74 (1999). https://doi.org/10.2165/00002018-199921010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199921010-00005

Keywords

Search

Navigation